MedTrace Logo

PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia

NCT00494897 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 374

Last updated 2009-05-19

No results posted yet for this study

Summary

The objective of current protocol is try improve the results of chemotherapy treatment in patients with ALL wich is not indicated the peripheral stem cell transplant in first remission, with an intensive consolidation follow by re-inductions.

Conditions

Interventions

DRUG

Asparaginase

DRUG

Cyclophosphamide

DRUG

Cytarabine

DRUG

Daunorubicin

DRUG

Mercaptopurine

DRUG

Prednisone

DRUG

Vincristine

DRUG

Methotrexate

PROCEDURE

Intrathecally treatment

Sponsors & Collaborators

  • PETHEMA Foundation

    lead OTHER

Principal Investigators

  • Ribera Josep Mª, Dr · Germans Trias i Pujol Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
15 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-06-30
Primary Completion
2007-05-31
Completion
2007-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00494897 on ClinicalTrials.gov